Adminstrative and Coordinating Core

行政协调核心

• 批准号: 8934529
• 负责人: Gregory D Kirk
• 金额: $ 13.41万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-19 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8934529
• 关键词: Accounting; Address; Advisory Committees; Aflatoxins; Africa; Africa South of the Sahara; Award; Biological Markers; Case-Control Studies; Cell Nucleus; Clinic; Clinical; Clinical Research; Collaborations; Communication; Communities; Computer software; Data; Data Base Management; Data Collection; Development; Documentation; Ensure; Epidemiology; Etiology; Face; Generations; Goals; Grant; HIV; Hepatitis B; Human; Immunosuppression; International; Intervention; Investigation; Laboratory Research; Lead; Leadership; Life; Link; Liver Cirrhosis; Mails; Malignant Neoplasms; Mentors; Monitor; Online Systems; Participant; Patients; Peer Review; Pilot Projects; Policies; Population Research; Premalignant; Preparation; Prevention strategy; Primary carcinoma of the liver cells; Principal Investigator; Problem Solving; Progress Reports; Public Relations; Publications; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Review Literature; Risk Management; Role; Site; Staging; Structure; Supervision; Training; Translational Research; Uganda; Universities; Work; career development; combat; data sharing; expectation; high risk; human subject protection; meetings; multidisciplinary; organizational structure; programs; repository; screening; symposium; treatment strategy; web site

Proposed is a collaborative partnership between Makerere University and Johns Hopkins on HIV and hepatocellular carcinoma (HCC) in Uganda: The H2U Consortium. Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live longer, the HCC burden will increase. The overarching goal of the Consortium is to reduce the heavy burden of HIV-associated HCC in sub-Saharan Africa. Building on long-standing collaborations, the Consortium expands will answer unresolved, high priority questions on the fundamental epidemiology and etiology of HIV-associated HCC, while expanding the clinical and laboratory research capacity in Uganda to address these issues. The Specific Aims include: 1) To enhance Ugandan investigator capacity for conducting high-level, collaborative, multidisciplinary scientific investigation of HIV-associated HCC; 2) To solidify the clinical, population and translational research infrastructure; 3) To advance the foundational understanding of the epidemiology, mechanisms, and clinical spectrum of HIV-associated HCC; and 4)To inform prevention and treatment strategies applicable to HIV-associated HCC in resource-limited settings. We propose two major clinical projects, including a large case-control study of 600 HCC cases and 600 controls to define the role of HIV and related immunosuppression. We also will screen 3000 HIV-infected clinic patients for pre-malignant liver cirrhosis and for high-risk hepatitis B and aflatoxin-related biomarkers, then follow this high-risk group with regular HCC screening to determine feasibility and whether early stage HCC can be identified. Our Developmental Core will implement the H2U Scholars Award, pairing a Ugandan investigator with a senior Hopkins mentor and supporting career development and a collaborative pilot project. The proposed studies will enhance our clinical and mechanistic understanding of HIV-associated HCC, provide evidence on appropriate treatment, and inform intervention strategies to combat HIV and HCC in Africa. The impact of our integrated research and capacity development activities will be establishment of the H2U Consortium as a Center of Excellence on HIV and HCC in Africa.

拟议的是Makerere大学与Johns Hopkins在乌干达的HIV和Hepatocellular癌（HCC）之间的合作伙伴关系：H2U财团。肝细胞癌（HCC）在非洲是一种非常普遍的致命癌症，随着HIV患者的寿命更长，HCC负担将增加。该财团的总体目标是减轻撒哈拉以南非洲与HIV相关的HCC的沉重负担。在长期合作的基础上，该财团扩展将回答有关HIV相关HCC的基本流行病学和病因的未解决的高优先问题，同时扩大了乌干达的临床和实验室研究能力，以解决这些问题。具体目的包括：1）提高乌干达研究人员进行高级，协作，多学科科学研究的能力； 2）巩固临床，人口和翻译研究基础设施； 3）提高对与HIV相关HCC的流行病学，机制和临床谱的基础理解； 4）为适用于资源有限的环境中适用于HIV相关的HCC的预防和治疗策略提供信息。我们提出了两个主要的临床项目，包括对600例HCC病例和600个对照的大型病例对照研究，以定义HIV和相关免疫抑制的作用。我们还将筛选3000名受HIV感染的诊所患者，以进行恶性肝硬化，以及高危丙型肝炎和黄曲霉毒素相关的生物标志物，然后跟随此高风险群体，具有常规的HCC筛查，以确定可行性以及是否可以鉴定出早期HCC。我们的发展核心将实施H2U学者奖，将乌干达调查员与霍普金斯高级导师配对，并支持职业发展和协作试点项目。拟议的研究将增强我们对与HIV相关的HCC的临床和机械理解，提供有关适当治疗的证据，并为在非洲打击HIV和HCC的干预策略。我们综合研究和能力开发活动的影响将是建立H2U财团作为非洲艾滋病毒和HCC卓越的中心。